测试版
试验雷达 AI
临床试验 NCT05998278 针对前列腺腺癌目前招募中。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情,或在此提出任何问题。
一个试验符合筛选条件
卡片视图

Personalized Optimization of Systematic Prostate Biopsy

招募中
临床试验详情主要以英语提供。然而,试验雷达 AI可以提供帮助!只需点击“解释临床试验”即可查看和讨论您选择的语言的试验信息。
临床试验NCT05998278是一项针对前列腺腺癌干预性研究试验,目前试验状态为招募中。试验始于2023年8月23日,计划招募664名患者。该研究由福建医科大学主导,预计于2025年12月30日完成。试验数据来源于ClinicalTrials.gov,最后更新时间为2025年2月20日
简要概括
Targeted biopsy combined systematic biopsy is the gold standard for diagnosis of prostate cancer. Excessive cores in systematic biopsy increases the risk of puncture trauma, bleeding and infection. On the basis of establishing a model with DRS stratification to reduce the cores of systematic biopsy, we propose the (12 cores -x) model innovatively. We hope that through this prospective study to verify the efficacy of the model and provide patients with a new biopsy model with high accuracy and fewer complications.

In this study, patients with suspected prostate cancer were randomly divided into two groups. Experimental group received targeted biopsy combined personalized systematic biopsy, and the control group received targeted biopsy combined systematic biopsy. The differences of the detection rate of Prostate cancer between the two groups were compared.

详细描述
In this study, patients with suspected prostate cancer were were enrolled at our institution, a public referral tertiary center. After written consent was obtained, patients were randomly assigned to either the intervention or control group in a 1:1 ratio using SPSS software by a research nurse with no clinical involvement in the trial. Once the allocation was established, neither patients nor investigators, including the member of the study who collected the data related to infectious events later, were blinded. Prior to biopsy, the following patient characteristics were obtained: age, BMI, serum PSA levels, location and size of the region of interest, and PIRADS-V2 score. Biopsy was performed by an experienced urologist using standard transperineal technique. The patient was placed in the lithotomy position and underwent either general anesthesia or local anesthesia (15 ml of 5% lidocaine was injected into the prostate capsule and apex under ultrasound guidance after the ultrasound probe was inserted transrectally for local anesthesia). Patients assigned to the experimental group were informed of the personalized systematic biopsy combined with targeted biopsy using the (12 cores -x) model (https://daringsky.shinyapps.io/prediction\_v2/), and the control group received targeted biopsy combined systematic biopsy. A biopsy core was obtained using an 18-gauge 25cm needle and a spring needle biopsy gun. The primary endpoint was the rate of prostate cancer diagnosis, including clinically significant cases. The secondary endpoints included pain scores and complications such as hematuria, perineal hematoma, urinary tract infection, and urinary retention.
官方标题

Research on Building "3+12-X" Personalized Prostate Precise Puncture Model with DRS Layered As the Core Based on Big Data MRI Images

疾病
前列腺腺癌
出版物
关于此临床试验发表的科学文章和研究论文:
其他研究标识符
  • 2022WSJK030
NCT编号
实际开始日期
2023-08-23
最近更新发布
2025-02-20
预计完成日期
2025-12-30
计划入组人数
664
研究类型
干预性研究
试验分期 (阶段)
不适用
试验状态
招募中
主要目的
诊断
分配方式
随机
干预模型
平行
盲法
单盲
试验组/干预措施
参与者组/试验组干预措施/治疗方法
实验性Experimental group
Experimental group received targeted biopsy plus personalized systematic biopsy
Personalized Optimization of Systematic Prostate Biopsy
Login the model based on our previous study (https://daringsky.shinyapps.io/prediction\_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
无干预Control group
Control group received targeted biopsy plus systematic biopsy
不适用
主要终点
结果指标度量标准描述时间框架
The detection rate of prostate cancer.
According to the pathological results after biopsy, the detection rate of prostate cancer was calculated.
3 months after biopsy
资格标准

适龄参与研究
成人, 老年人
最低年龄要求
50 Years
适龄性别
男性
  1. Patients with lesions found on rectal examination with any PSA value;
  2. Patients with abnormal lesions found on imaging with any PSA value;
  3. PSA >10.0 ng.ml-1;
  4. Patients with PSA of 4.0-10.0 ng.ml-1 and fPSA/tPSA < 0.16; (5 ) mpMRI was performed prior to biopsy and Prostate Imaging Reporting and Data System (PI-RADS V2.1) assessment category ≥3

(6) Willing to truthfully fill in the subject survey scale; (7) Willing to undergo follow-up; (8) The patient himself or his authorized immediate family member has signed the informed consent for clinical trial.

  1. previous biopsy cases;
  2. Patients who have undergone prostate-related surgery, radiotherapy, or anti-androgen therapy;
  3. Patients whopresented with severe hemorrhoids or rectal stenosis, rendering them intolerant to transrectal ultrasound
  4. clotting disordersPatients with severe systemic diseases, such as cardiovascular and cerebrovascular disorders, are not appropriate candidates for surgical intervention.
  5. unable to follow the plan.
研究中心联系人
联系人: Jiabing Zheng, +8613799422519, [email protected]
1 位于 1 个国家/地区的研究中心

Fujian

Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, 350000, China
Jiabing Zheng, 联系人, +8613799422519, [email protected]
招募中